Dagg tells Managing IP about being starstruck when dealing with Nobel Prize-winning inventors, and how she deals with self-doubt
Pharma counsel can look at suspicious packaging, online sellers and other signs to learn whether products are fake, say sources at Merck, Gilead and Organon
With the UPC almost here, pharma and biotech counsel are weighing the risks and rewards of the new system
Winners across 58 categories were revealed at the Andaz Hotel in London
UK Court of Appeal overturns Amazon judgment; GM takes Avanci patent licence; vaccine waiver draft released; IBM sues games maker
Counsel say Indian generic companies are starting to innovate and file invention patents but that they must scale up these activities to avoid becoming obsolete
Speakers at 3M, Mastercard and Merck revealed how they fought bad actors during a rise in fakes
Sources set out what different requirements for use and description and cancellation proceedings mean for their EU and US strategies
Russia has released a list of goods and trademarks that can be imported without permission, naming brands such as Apple, IBM and Samsung
Lawyers at Roche, Novartis and four other companies debate how tailored patent applications must be to overcome subject matter eligibility hurdles at the USPTO and EPO
The EU says it wants to make compulsory licensing rules more efficient, but neither drugmakers nor IP critics believe it will actually help produce more vaccines
Sources say patent thickets and pharmacy benefit managers are making it very difficult for generic pharma firms to compete in the US biosimilar space
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual Property
Jianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement -
Sponsored by Purplevine IP
Xiaojuan Yu of Purplevine IP Group discusses the medical device industry in China and considers why changes to the law are welcomed
-
Sponsored by FB Rice
Lee Miles of FB Rice discusses Australia’s patent box scheme which is set to introduce the agricultural and low emissions technology sectors
Companies in IP-intensive acquisitions must contend with freedom to operate and licences, say counsel at Siemens, Sanofi, USG and two law firms
Sources unpick why China’s share of European patent applications has been gradually growing, and predict a change in established norms
Attorneys who won and fought multimillion dollar trademark infringement awards say good stories are the key to success
Counsel at pharmaceutical companies say non-traditional marks can play an important role in portfolio management, but that regulatory concerns remain
Interviews; Exclusives
-
Opinion: Indian domestic policy must match WTO stand on IP waivers
India has been both urging for vaccine waivers before the WTO and refusing compulsory licensing in the country, but it’s not helping anyone
Phyllis Turner-Brim talks about her career, the need for balance in intellectual property policy and her passion for diversity and inclusion
Derek Gilliland, who became a magistrate judge at the Western District of Texas this month, delves into his work, thoughts on Alan Albright and ambitions
Kirupa Pushparaj talks about his move to a fintech start-up focused on young-person financial independence, career progression and start-up IP needs
Sources from the High Tech Inventors Alliance, the Senate Judiciary IP Subcommittee and NPE Dominion Harbor weigh in on the rise of the Western District of Texas
Heath Hoglund, chief patent counsel at Dolby in San Francisco, sits down with Managing IP to talk about licensing, FRAND and more
David Simon, senior vice president of IP at Salesforce, shares his views on Section 101, Fintiv, the DMCA, and more
The intellectual property CEO of one of the world's largest telecoms companies talks about licensing, harvesting collaboration and global outreach
In Managing IP’s first corner office podcast, Bryan Zielinski talks about his company’s IP challenges and opportunities, AI, and more
The Federal Circuit’s latest decision that Teva induced infringement has stakeholders worried that US skinny label law has been thrown out the window
In this Managing IP masterclass, IP directors from Thyssenkrupp and AB InBev discuss the challenges of managing a post-pandemic in-house team
